375 related articles for article (PubMed ID: 12171581)
21. Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives.
Urbina JA
J Eukaryot Microbiol; 2015; 62(1):149-56. PubMed ID: 25284065
[TBL] [Abstract][Full Text] [Related]
22. An update on benznidazole for the treatment of patients with Chagas disease.
Thakare R; Dasgupta A; Chopra S
Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658
[TBL] [Abstract][Full Text] [Related]
23. Trypanocidal effect of the benzyl ester of N-propyl oxamate: a bi-potential prodrug for the treatment of experimental Chagas disease.
Wong-Baeza C; Nogueda-Torres B; Serna M; Meza-Toledo S; Baeza I; Wong C
BMC Pharmacol Toxicol; 2015 Apr; 16():10. PubMed ID: 25896924
[TBL] [Abstract][Full Text] [Related]
24. Role of nucleic acid amplification assays in monitoring treatment response in chagas disease: Usefulness in clinical trials.
Sulleiro E; Muñoz-Calderon A; Schijman AG
Acta Trop; 2019 Nov; 199():105120. PubMed ID: 31376368
[TBL] [Abstract][Full Text] [Related]
25. Trypanosoma cruzi trypanothione reductase inhibitors: phenothiazines and related compounds modify experimental Chagas' disease evolution.
Rivarola HW; Paglini-Oliva PA
Curr Drug Targets Cardiovasc Haematol Disord; 2002 Jun; 2(1):43-52. PubMed ID: 12769656
[TBL] [Abstract][Full Text] [Related]
26. Response to chemotherapy with benznidazole of clones isolated from the 21SF strain of Trypanosoma cruzi (biodeme Type II, Trypanosoma cruzi II).
Campos RF; Guerreiro ML; Sobral Kde S; Lima Rde C; Andrade SG
Rev Soc Bras Med Trop; 2005; 38(2):142-6. PubMed ID: 15821788
[TBL] [Abstract][Full Text] [Related]
27. Assessing antibody decline after chemotherapy of early chronic Chagas disease patients.
Murphy N; Cardinal MV; Bhattacharyya T; Enriquez GF; Macchiaverna NP; Alvedro A; Freilij H; Martinez de Salazar P; Molina I; Mertens P; Gilleman Q; Gürtler RE; Miles MA
Parasit Vectors; 2021 Oct; 14(1):543. PubMed ID: 34670602
[TBL] [Abstract][Full Text] [Related]
28. Chagas disease: Present status of pathogenic mechanisms and chemotherapy.
Maya JD; Orellana M; Ferreira J; Kemmerling U; López-Muñoz R; Morello A
Biol Res; 2010; 43(3):323-31. PubMed ID: 21249304
[TBL] [Abstract][Full Text] [Related]
29. Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives.
Braga MS; Lauria-Pires L; Argañaraz ER; Nascimento RJ; Teixeira AR
Rev Inst Med Trop Sao Paulo; 2000; 42(3):157-61. PubMed ID: 10887376
[TBL] [Abstract][Full Text] [Related]
30. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
[TBL] [Abstract][Full Text] [Related]
31. New 1,2,3-triazole-based analogues of benznidazole for use against Trypanosoma cruzi infection: In vitro and in vivo evaluations.
Leite DI; Fontes FV; Bastos MM; Hoelz LVB; Bianco MDCAD; de Oliveira AP; da Silva PB; da Silva CF; Batista DDGJ; da Gama ANS; Peres RB; Villar JDF; Soeiro MNC; Boechat N
Chem Biol Drug Des; 2018 Sep; 92(3):1670-1682. PubMed ID: 29745048
[TBL] [Abstract][Full Text] [Related]
32. [Nifurtimox, a bright future for treatment of Chagas disease].
Wolf A; Boulliat C; Coillot C; Rouault M; Gaillard K; Beranger C; Oliver M
Med Trop (Mars); 2011 Apr; 71(2):131-3. PubMed ID: 21695868
[TBL] [Abstract][Full Text] [Related]
33. [Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation].
Coura JR; de Abreu LL; Willcox HP; Petana W
Rev Soc Bras Med Trop; 1997; 30(2):139-44. PubMed ID: 9148337
[TBL] [Abstract][Full Text] [Related]
34. Challenges in Chagas Disease Drug Discovery: A Review.
Paucar R; Moreno-Viguri E; Pérez-Silanes S
Curr Med Chem; 2016; 23(28):3154-3170. PubMed ID: 27356544
[TBL] [Abstract][Full Text] [Related]
35. Specific chemotherapy of Chagas disease: controversies and advances.
Urbina JA; Docampo R
Trends Parasitol; 2003 Nov; 19(11):495-501. PubMed ID: 14580960
[No Abstract] [Full Text] [Related]
36. Developments on treatment of Chagas disease - from discovery to current times.
Custodio Leite TO
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2576-2586. PubMed ID: 30964186
[TBL] [Abstract][Full Text] [Related]
37. The chemotherapy of chagas' disease: an overview.
Paulino M; Iribarne F; Dubin M; Aguilera-Morales S; Tapia O; Stoppani AO
Mini Rev Med Chem; 2005 May; 5(5):499-519. PubMed ID: 15892691
[TBL] [Abstract][Full Text] [Related]
38. A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease.
Araújo MS; Martins-Filho OA; Pereira ME; Brener Z
J Antimicrob Chemother; 2000 Jun; 45(6):819-24. PubMed ID: 10837436
[TBL] [Abstract][Full Text] [Related]
39. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease.
Corrales M; Cardozo R; Segura MA; Urbina JA; Basombrío MA
Antimicrob Agents Chemother; 2005 Apr; 49(4):1556-60. PubMed ID: 15793138
[TBL] [Abstract][Full Text] [Related]
40. [What is not searched, it is difficult to find: Chagas' disease].
Briceno L; Mosca W
G Ital Cardiol (Rome); 2016 May; 17(5):343-7. PubMed ID: 27310907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]